Mental wellness company Nue Life Health has announced the completion of its Series A equity financing led by Obvious Ventures.
The Shift Network is presenting the Psychedelic Healing Summit — a free, four-day online event featuring leading voices in the field of psychedelics.
SABI Mind and Reverie Psychedelics have partnered to expand research into psychedelic-assisted therapies.
Delic Holdings Corp subsidiary, Delic Labs, has received a Health Canada 56 Research Exemption that will allow scientists to conduct research and perform tests on psychedelic and...
Freedom to Operate has published its new study that can be used to fight back against anyone attempting to patent a polymorphic form of LSD and...
Numinus’ acquisition of Novamind will see the complementary businesses create a North American platform for psychedelic therapy and research.
Results from two-combined studies have revealed that psilocybin-assisted therapy increased brain activity in people with depression for up to three weeks following use.
Canadian-based Lophos Pharmaceuticals is engaging KGK Science to evaluate a path to market for sustainably-grown peyote-derived natural health products.
Entheon Biomedical has announced an improved genetic screening platform that includes the brain-derived neurotrophic factor (BDNF) gene.
Cybin Inc.
The first healthy, psychedelic-naïve volunteers have been dosed in Beckley Psytech’s Phase I clinical trial assessing safety and pharmacokinetics of its second innovative formulation of 5-MeO-DMT...
HMNC Brain Health and Develco Pharma have announced promising top-line results from the Phase II proof-of-concept investigator-initiated trial of its oral prolonged-release formulation of ketamine (KET01)...
